150
Participants
Start Date
April 30, 2016
Primary Completion Date
December 31, 2020
Study Completion Date
April 30, 2021
Thalidomide (100mg)
Patients were randomly assigned to receive a 120-days course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
Thalidomide (50mg)
Patients were randomly assigned to receive a 120-days course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
placebo
Patients were randomly assigned to receive a 120-days course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
Peking Union Medical College Hospital, Beijing
Ruijin Hospital, Shanghai
Shanghai Zhongshan Hospital, Shanghai
Huashan Hospital, Shanghai
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Department of Gastroenterology, Renji Hospital, Shanghai Institute of Digestive Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai
Changhai Hospital, Shanghai
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Xinqiao Hospital of Chongqing, Chongqing
Nanfang Hospital of Southern Medical University, Guangzhou
Peking Union Medical College Hospital
OTHER
Nanfang Hospital, Southern Medical University
OTHER
Xinqiao Hospital of Chongqing
OTHER
Changhai Hospital
OTHER
Shanghai Zhongshan Hospital
OTHER
Huashan Hospital
OTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Ruijin Hospital
OTHER
Shanghai Jiao Tong University School of Medicine
OTHER